Prescient Therapeutics (ASX:PTX) OCF Margin %: 0.00% (As of Dec. 2025)


What is Prescient Therapeutics OCF Margin %?

Prescient Therapeutics ASX:PTX +13.79% OCF Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Prescient Therapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Prescient Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-6.54 Mil. Prescient Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Prescient Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Prescient Therapeutics's current OCF Yield % is -11.18%.

The historical rank and industry rank for Prescient Therapeutics's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Prescient Therapeutics was -14172.73%. The lowest was -14172.73%. And the median was -14172.73%.

ASX:PTX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Prescient Therapeutics OCF Margin % Related Terms

Prescient Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics OCF Margin % Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Prescient Therapeutics's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.244/0
= %

Prescient Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.543/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Prescient Therapeutics (ASX:PTX) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Prescient Therapeutics and its competitors. According to the industry distribution chart, Prescient Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Prescient Therapeutics' OCF Margin % too high?
Prescient Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Prescient Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Prescient Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prescient Therapeutics ranks #999999 out of 960 companies for OCF Margin %. This places Prescient Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (ASX:PTX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Prescient Therapeutics (ASX:PTX), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.